220 related articles for article (PubMed ID: 31985870)
41. The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a prospective, randomised crossover study.
Kessler CM; Friedman K; Schwartz BA; Gill JC; Powell JS;
Thromb Haemost; 2011 Aug; 106(2):279-88. PubMed ID: 21725579
[TBL] [Abstract][Full Text] [Related]
42. The evaluation of factor VIII binding activity of von Willebrand factor by means of an ELISA method: significance and practical implications.
Casonato A; Pontara E; Zerbinati P; Zucchetto A; Girolami A
Am J Clin Pathol; 1998 Mar; 109(3):347-52. PubMed ID: 9495210
[TBL] [Abstract][Full Text] [Related]
43. Diagnosis of von Willebrand disease type 2N: a simplified method for measurement of factor VIII binding to von Willebrand factor.
Miller CH; Kelley L; Green D
Am J Hematol; 1998 Aug; 58(4):311-8. PubMed ID: 9692396
[TBL] [Abstract][Full Text] [Related]
44. A genetic association study of activated partial thromboplastin time in European Americans and African Americans: the ARIC Study.
Weng LC; Cushman M; Pankow JS; Basu S; Boerwinkle E; Folsom AR; Tang W
Hum Mol Genet; 2015 Apr; 24(8):2401-8. PubMed ID: 25552651
[TBL] [Abstract][Full Text] [Related]
45. Rare and low-frequency variants and their association with plasma levels of fibrinogen, FVII, FVIII, and vWF.
Huffman JE; de Vries PS; Morrison AC; Sabater-Lleal M; Kacprowski T; Auer PL; Brody JA; Chasman DI; Chen MH; Guo X; Lin LA; Marioni RE; Müller-Nurasyid M; Yanek LR; Pankratz N; Grove ML; de Maat MP; Cushman M; Wiggins KL; Qi L; Sennblad B; Harris SE; Polasek O; Riess H; Rivadeneira F; Rose LM; Goel A; Taylor KD; Teumer A; Uitterlinden AG; Vaidya D; Yao J; Tang W; Levy D; Waldenberger M; Becker DM; Folsom AR; Giulianini F; Greinacher A; Hofman A; Huang CC; Kooperberg C; Silveira A; Starr JM; Strauch K; Strawbridge RJ; Wright AF; McKnight B; Franco OH; Zakai N; Mathias RA; Psaty BM; Ridker PM; Tofler GH; Völker U; Watkins H; Fornage M; Hamsten A; Deary IJ; Boerwinkle E; Koenig W; Rotter JI; Hayward C; Dehghan A; Reiner AP; O'Donnell CJ; Smith NL
Blood; 2015 Sep; 126(11):e19-29. PubMed ID: 26105150
[TBL] [Abstract][Full Text] [Related]
46. The defective interaction between von Willebrand factor and factor VIII in a patient with type 1 von Willebrand disease is caused by substitution of Arg19 and His54 in mature von Willebrand factor.
Kroner PA; Foster PA; Fahs SA; Montgomery RR
Blood; 1996 Feb; 87(3):1013-21. PubMed ID: 8562925
[TBL] [Abstract][Full Text] [Related]
47. Influences of ABO blood group, age and gender on plasma coagulation factor VIII, fibrinogen, von Willebrand factor and ADAMTS13 levels in a Chinese population.
Wang Z; Dou M; Du X; Ma L; Sun P; Cao H; Ye S; Jiang P; Liu F; Lin F; Zhang R; Li C
PeerJ; 2017; 5():e3156. PubMed ID: 28382235
[TBL] [Abstract][Full Text] [Related]
48. The relationship between ABO histo-blood group, factor VIII and von Willebrand factor.
O'Donnell J; Laffan MA
Transfus Med; 2001 Aug; 11(4):343-51. PubMed ID: 11532189
[TBL] [Abstract][Full Text] [Related]
49. Biological and genetic factors influencing plasma factor VIII levels in a healthy family population: results from the Stanislas cohort.
Morange PE; Tregouet DA; Frere C; Saut N; Pellegrina L; Alessi MC; Visvikis S; Tiret L; Juhan-Vague I
Br J Haematol; 2005 Jan; 128(1):91-9. PubMed ID: 15606554
[TBL] [Abstract][Full Text] [Related]
50. von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis.
Nossent AY; VAN Marion V; VAN Tilburg NH; Rosendaal FR; Bertina RM; VAN Mourik JA; Eikenboom HC
J Thromb Haemost; 2006 Dec; 4(12):2556-62. PubMed ID: 17059421
[TBL] [Abstract][Full Text] [Related]
51. Management of von Willebrand disease with factor VIII/von Willebrand factor concentrates: results from current studies and surveys.
Federici AB
Blood Coagul Fibrinolysis; 2005 Apr; 16 Suppl 1():S17-21. PubMed ID: 15849522
[TBL] [Abstract][Full Text] [Related]
52. A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice.
Yee A; Gildersleeve RD; Gu S; Kretz CA; McGee BM; Carr KM; Pipe SW; Ginsburg D
Blood; 2014 Jul; 124(3):445-52. PubMed ID: 24850761
[TBL] [Abstract][Full Text] [Related]
53. Coagulation biomarkers are independent predictors of increased oxygen requirements in COVID-19.
Rauch A; Labreuche J; Lassalle F; Goutay J; Caplan M; Charbonnier L; Rohn A; Jeanpierre E; Dupont A; Duhamel A; Faure K; Lambert M; Kipnis E; Garrigue D; Lenting PJ; Poissy J; Susen S
J Thromb Haemost; 2020 Nov; 18(11):2942-2953. PubMed ID: 32881304
[TBL] [Abstract][Full Text] [Related]
54. Elevated levels of factor VIII and subsequent risk of all-cause mortality: results from the MEGA follow-up study.
Yap ES; Timp JF; Flinterman LE; van Hylckama Vlieg A; Rosendaal FR; Cannegieter SC; Lijfering WM
J Thromb Haemost; 2015 Oct; 13(10):1833-42. PubMed ID: 26264493
[TBL] [Abstract][Full Text] [Related]
55. Abnormal binding of factor VIII is linked with the substitution of glutamine for arginine 91 in von Willebrand factor in a variant form of von Willebrand disease.
Kroner PA; Friedman KD; Fahs SA; Scott JP; Montgomery RR
J Biol Chem; 1991 Oct; 266(29):19146-9. PubMed ID: 1918030
[TBL] [Abstract][Full Text] [Related]
56. Factor VIII, Protein C and Cardiovascular Disease Risk: The REasons for Geographic and Racial Differences in Stroke Study (REGARDS).
Zakai NA; Judd SE; Kissela B; Howard G; Safford MM; Cushman M
Thromb Haemost; 2018 Jul; 118(7):1305-1315. PubMed ID: 29890521
[TBL] [Abstract][Full Text] [Related]
57. The endothelial lectin clearance receptor CLEC4M binds and internalizes factor VIII in a VWF-dependent and independent manner.
Swystun LL; Notley C; Georgescu I; Lai JD; Nesbitt K; James PD; Lillicrap D
J Thromb Haemost; 2019 Apr; 17(4):681-694. PubMed ID: 30740857
[TBL] [Abstract][Full Text] [Related]
58. Distinct roles of Ser-764 and Lys-773 at the N terminus of von Willebrand factor in complex assembly with coagulation factor VIII.
Castro-Núñez L; Bloem E; Boon-Spijker MG; van der Zwaan C; van den Biggelaar M; Mertens K; Meijer AB
J Biol Chem; 2013 Jan; 288(1):393-400. PubMed ID: 23168412
[TBL] [Abstract][Full Text] [Related]
59. The D' domain of von Willebrand factor requires the presence of the D3 domain for optimal factor VIII binding.
Przeradzka MA; Meems H; van der Zwaan C; Ebberink EHTM; van den Biggelaar M; Mertens K; Meijer AB
Biochem J; 2018 Sep; 475(17):2819-2830. PubMed ID: 30111575
[TBL] [Abstract][Full Text] [Related]
60. Determinants of factor VIII plasma levels in carriers of haemophilia A and in control women.
Ay C; Thom K; Abu-Hamdeh F; Horvath B; Quehenberger P; Male C; Mannhalter C; Pabinger I
Haemophilia; 2010 Jan; 16(1):111-7. PubMed ID: 19758307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
